Drugs / FOLFIRI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07337447 | Apr 2026 → Apr 2029 expected | neuroendocrine carcinoma | Hospices Civils de Lyon | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04259944 | Jun 2020 → Jul 2024 | colon carcinoma | IFOM ETS - The AIRC Institute of Molecular Oncology | Unknown | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT06867822 Background | Jul 2025 → Jul 2027 expected | colorectal cancer | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 1 | NCT06179160 Background | Jan 2024 → Jan 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04247256 Background | May 2020 → Jun 2022 | colorectal cancer | Scandion Oncology A/S | Unknown | No outcome recorded |
| Phase 1/2 | NCT02568046 Background | Mar 2016 → May 2017 | colorectal cancer | Symphogen A/S | Terminated | No outcome recorded |
| Phase 2 | NCT05634590 Background | Dec 2022 → Dec 2025 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT05362617 Background | Jan 2020 → Dec 2022 | colorectal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-05-27 | Scandion Oncology A/S | Scandion Oncology announces that the first patient has received treatment with SCO-101 in combination with FOLFIRI. scandiononcology.com ↗ |
| 2012-08-16 | Oncolytics Biotech | Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase I Clinical Trial Investigating REOLYSIN® in Combination with FOLFIRI in Patients with Colorectal Cancer oncolyticsbiotech.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOLFIRI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07337447 ↗ |
| Known as | Fluorouracil (5-FU) | “Fluorouracil (5-FU)” NCT02568046 ↗ |
| Modality | Other / unclassified | “FOLFIRI is a key anti-cancer chemotherapeutic combination in the treatment of several solid tumor cancers, e.g. colorectal cancer.” NCT04247256 ↗ |
| Route | Intravenous | “5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours)” NCT02568046 ↗ |